Compass Therapeutics, Inc. (CMPX)
2.52
+0.12
(+5.00%)
USD |
NASDAQ |
Aug 25, 16:00
2.52
0.00 (0.00%)
After-Hours: 17:21
Compass Therapeutics PS Ratio
PS Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PS Ratio Data
| Date | Value |
|---|---|
| June 27, 2025 | 415.05 |
| June 26, 2025 | 421.53 |
| June 25, 2025 | 436.12 |
| June 24, 2025 | 424.77 |
| June 23, 2025 | 411.80 |
| June 20, 2025 | 389.11 |
| June 18, 2025 | 385.86 |
| June 17, 2025 | 355.06 |
| June 16, 2025 | 384.24 |
| June 13, 2025 | 390.73 |
| June 12, 2025 | 390.73 |
| June 11, 2025 | 393.97 |
| June 10, 2025 | 406.94 |
| June 09, 2025 | 416.67 |
| June 06, 2025 | 405.32 |
| June 05, 2025 | 382.62 |
| June 04, 2025 | 351.82 |
| June 03, 2025 | 346.95 |
| June 02, 2025 | 348.57 |
| May 30, 2025 | 340.47 |
| May 29, 2025 | 343.71 |
| May 28, 2025 | 340.47 |
| May 27, 2025 | 342.09 |
| May 23, 2025 | 338.85 |
| May 22, 2025 | 340.47 |
| Date | Value |
|---|---|
| May 21, 2025 | 333.98 |
| May 20, 2025 | 340.47 |
| May 19, 2025 | 342.09 |
| May 16, 2025 | 340.47 |
| May 15, 2025 | 327.50 |
| May 14, 2025 | 324.26 |
| May 13, 2025 | 324.26 |
| May 12, 2025 | 325.88 |
| May 09, 2025 | 295.07 |
| May 08, 2025 | 288.59 |
| May 07, 2025 | 285.34 |
| May 06, 2025 | 274.00 |
| May 05, 2025 | 301.56 |
| May 02, 2025 | 306.42 |
| May 01, 2025 | 295.07 |
| April 30, 2025 | 301.56 |
| April 29, 2025 | 298.31 |
| April 28, 2025 | 308.04 |
| April 25, 2025 | 314.53 |
| April 24, 2025 | 343.71 |
| April 23, 2025 | 335.60 |
| April 22, 2025 | 321.01 |
| April 21, 2025 | 288.59 |
| April 17, 2025 | 283.72 |
| April 16, 2025 | 275.62 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| Upstream Bio, Inc. | 123.38 |
| ACADIA Pharmaceuticals, Inc. | 4.616 |
| Alnylam Pharmaceuticals, Inc. | 6.869 |
| Anika Therapeutics, Inc. | 2.512 |
| Savara, Inc. | -- |
PS Ratio Related Metrics
| Price to Book Value | 2.733 |
| Price | 2.52 |
| Earnings Yield | -15.97% |
| Market Cap | 453.82M |